The selective apoptotic effect of Apoptin is neither dependent on p53 protein-mediated nor inhibited by the overexpression of Bcl-2, and therefore, it is regarded as a new type of biologically active antitumoral protein, which is expected to improve tumor gene therapy [4–7]. The gene discussed is TP53; the disease is neoplasm.